Fast Locator 2011-2012: Xcelience, LLC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Xcelience, LLC



Xcelience is a premier provider of formulation development and manufacturing solutions with a solid reputation for accelerating early phase small molecule development. Our outstanding quality record, significant drug development expertise, willingness to customize, and disciplined project management enable us to deliver real advantage to clients with the need to speed potential drugs to clinical trials.

Since 1997, Xcelience has been renowned for reliably expediting drug product development for oral solid, semi-solid and liquid dosage forms. Our formulation development scientists have considerable experience overcoming challenging associated with physical and chemical properties of drug substance, or limited quantities of active pharmaceutical ingredient (API), in a manner that results in compounds with improved solubility and bioavailability. Xcelience operates out of a cGMP compliant, FDA audited, DEA licensed facility in Tampa, Florida.

Xcelience is more than just the market leader for powder-in-capsule services, which enable clients to fill very small amounts of API into capsule and reduce time to first-in-human studies by as much as 45% relative to traditional drug development programs, we are a full spectrum formulation development and manufacturing provider. Our recently expanded process technology capabilities reflect our continued commitment to help clients build towards improved manufacturing outcomes in a manner consistent with the FDA’s Quality by Design initiative.


Regions where services are provided:

North America and Europe


Outsourcing serivces provided:

Development and Phase I/IICTM

  • Solid dose, semisolids, and liquids development
  • Process development-small molecule

Analytical Services

  • Chemistry and stability
  • Particle characterization

Packaging and Logistics

  • Clinical labels
  • Clinical packaging and distribution

Contact:

Partnering with a specialist like Xcelience for early phase development can reduce product risk and accelerate drug development timelines. For more information, contact Xcelience at 608.643.4444 or visit www.xcelience.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
20%
Attracting a skilled workforce
28%
Obtaining/maintaining adequate financing
12%
Regulatory compliance
40%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here